Comparing the AstraZeneca (British) and Sinovac (Chinese) COVID-19 Vaccines
The University of Oxford and AstraZeneca have teamed up in the United Kingdom to produce a recombinant vaccine made from a modified chimpanzee adenovirus. Another candidate is from China’s Sinovac Biotech. The Sinovac vaccine uses more traditional vaccine technology, relying on inactivated virus particles to produce an immune response.
Neither of these vaccines has been approved for regular or emergency use in the United States yet.
Answers & Comments
Comparing the AstraZeneca (British) and Sinovac (Chinese) COVID-19 Vaccines
The University of Oxford and AstraZeneca have teamed up in the United Kingdom to produce a recombinant vaccine made from a modified chimpanzee adenovirus. Another candidate is from China’s Sinovac Biotech. The Sinovac vaccine uses more traditional vaccine technology, relying on inactivated virus particles to produce an immune response.
Neither of these vaccines has been approved for regular or emergency use in the United States yet.
AstraZeneca Sinovac
Official name
AZD1222 CoronaVac
Effectiveness
76% 56%–65%
Trusted Source Dosage
2 doses, 28 days apart
2 doses, 21 days apart
Storage
standard refrigeration
standard refrigeration
Type
chimpanzee adenovirus
inactivated virus
Approval status
U.S. and international clinical trials
Various international clinical trials
U.S. availability
300 million doses owned, but not approved for use
none
pa brainliest po